For decades, no cancer therapy had been shown to improve average survival in metastatic melanoma. Two critical events have occurred, the discovery of melanoma driver mutation subsets and the discovery of immune checkpoint inhibitors, which have allowed for the development of modern, effective therapies. This review will discuss recently approved novel agents and select drugs in development in advanced melanoma.
INTRODUCTION
Melanoma has held a designation of ill repute among cancer subtypes, being a disease that has been resistant to modern chemotherapeutic approaches and results in the rapid demise of patients who are in the prime of their life. Up until a couple of years ago, typical treatments included chemotherapy drugs such as dacarbazine (DTIC) and temozolomide, which had low response rates and no improvement in overall survival [1] . Additionally, early attempts at immune therapy in the form of cytokines, such as interferon and interleukin-2 (IL-2), also had low response rates with high toxicity levels [2] . In the setting of these therapies, a metastatic melanoma patient's average survival was 6-8 months, and no agent had been able to improve on this outcome in numerous randomized clinical trials [3] .
Fortunately, a new generation of therapies for metastatic melanoma has arisen in the last few years resulting in improvements in response rates and overall survival outcomes. These advancements have taken place primarily on two separate fronts: (1) molecularly targeted inhibitors that work within the melanoma cell against abnormally activated protein kinases and (2) immune checkpoint inhibitors that work by enhancing T-lymphocyte function.
Vemurafenib and ipilimumab represent the first in class of each of these approaches, respectively, and both agents have shown improved average overall survival outcomes for metastatic melanoma patients in randomized trials. Several other agents in both classes have subsequently emerged, continuing to improve clinical outcomes. This review will focus on the clinical development of modern novel melanoma molecularly targeted agents and immune checkpoint inhibitors, as well as combination approaches.
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
DEVELOPMENT OF THERAPIES TARGETING DRIVER MUTATIONS IN MELANOMA
Targeting the BRAF Pathway in Advanced
Melanoma
The molecular biology of melanoma is complicated with numerous mutations present and a variety of pathways impacted ( Fig. 1) . in approximately 50% of melanomas), leading to the theory that the BRAF serine/threonine kinase could represent a commonly applicable therapeutic target [4] . In about 80-90% of mutated BRAF tumors, an activating V600E missense mutation is present, while about 10-20% of BRAF mutant tumors have V600K, V600D, and V600R mutations [5] . These activating mutations result in constitutive activation of the MAP (mitogen-activated protein) kinase pathway resulting in unchecked cell proliferation.
A landmark phase I trial of a potent BRAF V600 inhibitor PLX-4032 (now known as vemurafenib) demonstrated proof of principle that this targeted therapy approach could work [6] . This study demonstrated high response rates and acceptable tolerability, which led to further clinical development of the drug. A phase III study (BRIM-3) comparing vemurafenib with dacarbazine was performed with co-primary endpoints of overall survival (OS) and PFS [7] . This study included 675 patients with metastatic melanoma (95%) or unresectable stage IIIC (5%) with a BRAF V600E mutation who were previously untreated and showed a statistically significant improvement in survival for those treated with vemurafenib compared to dacarbazine [median OS 13.6 versus 9.7 months, respectively (HR 0.70, p = 0.0008)] [8]. The median PFS was also significantly prolonged with vemurafenib use at 6.9 months compared to 1.6 months for dacarbazine (HR 0.26, p\0.001). Based on these results, the FDA approved vemurafenib for the treatment of BRAF V600E mutant metastatic melanoma in 2011. An increased incidence of cutaneous squamous cell carcinomas and keratoacanthomas has been noted with vemurafenib and other BRAF inhibitor therapies. In a study that analyzed three trials with a total of 520 patients who received vemurafenib, the incidence of squamous cell carcinoma was noted to be 19-26%, mostly keratoacanthomas [9] . The majority of patients continued therapy without dose reduction after resection. The SCC seems to be due to a paradoxical activation of the MAPK pathway that bypasses BRAF inhibition, as mentioned above [10] .
Following on the footsteps of vemurafenib has been the development of other novel potent kinase inhibitors. Dabrafenib, similar to vemurafenib, is a potent inhibitor of mutant V600 BRAF kinase and has also been studied in a randomized phase III (BREAK-3) trial evaluating its activity against dacarbazine in patients with metastatic V600 mutated melanoma [11] [12] [13] . This study has the potential to show benefit of a more individualized approach in patients with emerging or pre-existing mutations that promote resistance to primary MAP kinase pathway inhibition. Studies evaluating combinations to overcome the PI3 kinase pathway resistance mechanism are also ongoing (NCT01512251, NCT01902173).
Targeting Pathways in Other Melanoma Subsets
Evaluation of targeted treatments for melanoma patients whose tumors harbor mutations other than BRAF is also underway. The NRAS kinase is mutated in about 15-25% of untreated melanoma tumors. It is seen in about 20% of BRAF mutant patients who progressed on BRAF inhibitor therapy, but very rarely coexists with BRAF mutation prior to a BRAF inhibitor exposure [28] . Like BRAF, NRAS is a driver mutation, and it can activate multiple downstream pathways including the MAPK pathway through BRAF or CRAF and PI3K.
NRAS mutations are usually seen in an older population and where chronic UV exposure has been present. Compared to BRAF mutant tumors, the NRAS mutation tends to be present in thicker tumors with a higher mitosis rate and is arguably more aggressive than BRAF mutated tumors [29, 30] . Targeting in patients with metastatic NRAS mutant melanoma (n = 117) were reported in September 2014 [32] . An ORR of 14.5% was observed including one person who achieved complete CR. Survival endpoints were also reported including a median PFS of 3.6 months (95% CI 2.6-3.8 months) and a median OS of 12.2 months (lower 95% CI of 7.9 months). Based on the efficacy noted in this study, a randomized phase 3 trial (NEMO) was launched and is currently ongoing in metastatic NRAS mutant melanoma patients comparing binimetinib to dacarbazine.
The use of MEK inhibitors may also play a role in a rarer melanoma subtype, ocular melanoma, which is also driven by MAP kinase pathway activation. Ocular melanoma is a type of melanoma typically excluded from melanoma trials because of its notoriously treatment-resistant nature, rapid rate of progression, and different genetics (high frequency of GNAQ and GNA11 mutations).
In a recently reported study, the MEK inhibitor, selumetinib, was compared to temozolomide chemotherapy and showed a PFS of 15.9 weeks compared to 7 weeks, respectively (HR = 0.46, p\0.001) [33] . Median OS was 9.1 vs.
11.8 months in the selumetinib arm (HR 0.66, p = 0.09). Although overall survival did not reach statistical significance, this was the first randomized trial to show a statistical improvement in PFS, which is a meaningful advance forward for this disease that lacks therapeutic options.
The growth factor receptor, c-kit, also plays an important role in a small subset of melanoma patients. Up to 20% of patients with mucosal, chronic sun-damaged and acral lentigeninous melanomas have mutations in c-kit, which drives pathogenesis in these tumors [34] . A variety of agents, including imatinib, dasatinib, sunitinib, and nilotinib potently, inhibits the ckit receptor and trials with the agents have either been performed or are currently ongoing. The most experience with targeted therapy in kit-mutant melanoma has been with imatinib, with several phase 2 trials being reported [35] [36] [37] [38] [39] . In non-enriched patients for kit-activating mutations, the efficacy of imatinib has been rather disappointing; however, this is not the case in patients who are selected by a specific activating mutation (e.g., exon 9, 11, 13 mutations). In a study by Hodi et al., imatinib was tested in advanced melanoma patients with kit mutations or amplification [38] . In this study, the ORR was 29%, which was significantly better than the null value of 5%. The response rate was highest in those with activating mutations with a 51% response rated. Median time to progression was relatively brief (3.9 months for the mutated group, 3.4 months for the amplified group), and median overall survival was 12.5 months. In a trial evaluating the kit inhibitor nilotinib, patients with advanced melanoma harboring kit alterations that were refractory to imatinib were studied [40] . The response rate for this approach was 18% with a median TTP of 3.3 months and OS of 9.1 months. Notably, no responses were seen in a separate cohort exploring those with brain metastases. However, in cases of symptomatic progression, waiting for delayed response can be challenging and in certain situations impractical.
TARGETING ADVANCED MELANOMA WITH NOVEL IMMUNE CHECKPOINT INHIBITORS
Ipilimumab therapy has also been associated with distinctive immune-related adverse events (IRAEs). These IRAEs can include colitis, dermatitis, hepatitis, endocrinopathies and neuropathies, all of which are related to an inflammatory effect of lymphocyte activation. While most individuals had tolerable side effects, severe immune-related adverse events (grade 3 or higher) were noted in 10-15% of patients treated with ipilimumab.
Based on the results of these data, ipilimumab was FDA approved in March 2011. A subsequent phase 3 placebo-controlled trial evaluated 502 previously untreated patients with metastatic melanoma using a higher dose of ipilimumab (10 mg/kg as compared to 3 mg/kg) in combination with dacarbazine vs. dacarbazine alone [43] . This trial also showed a significant improvement in its primary endpoint of OS, with those receiving the ipilimumab/dacarbazine combination having a median OS of 11.2 months compared to 9.2 months for dacarbazine alone (HR 0.72, p\0.001).
PD-1 Inhibition
Like CTLA-4, the programmed death-1 (PD-1) receptor is an important negative regulator of T-lymphocyte activity (inhibitory checkpoint) [44] . PD-1 interacts with the PD-1 ligand (PD-L1), which can be expressed on a variety 6-month PFS rates of 34, 38, and 16 percent for the 2 and 10 mg/kg pembrolizumab arms and the chemotherapy arm, respectively [46] . Treatment-related grade 3 or higher adverse events occurred in 11% of patients in the 2 mg/ kg arm, 14% in the 10 mg/kg arm, and 26% with chemotherapy. In the phase 3 Keynote-006 trial, 834 patients with unresectable or metastatic melanoma who had received no more than one prior systemic therapy (required to be CTLA-4 and PD-1 inhibitor naïve) were randomized to receive pembrolizumab at 10 mg/kg every ipilimumab 3 mg/kg every 3 weeks [47] . In this study, both pembrolizumab arms appeared to have similar efficacy outcomes, and both were superior to ipilimumab in the studies primary endpoints of PFS and OS. The median PFS for the q2 week pembrolizumab regimen was 5.5 months compared to 4.1 months for the q3 week regimen and 2.8 months for ipilimumab (HR 0.58, p\0.001 for q2 week regimen versus ipilimumab). The median OS has not been reached for any of the groups at the time of publication; however, the 12-month survival landmark demonstrated a survival of 74.1% (q2 week pembrolizumab), 68.4% (q3 week), and 58.2% (ipilimumab). The difference between the pembrolizumab arms was statistically superior to ipilimumab for the
12-month OS analysis (HR 0.63).
Nivolumab is a fully human monoclonal PD-1 blocking antibody and has also been extensively evaluated in a series of phase 3 trials in advanced melanoma patients. The FDA approved the use of nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor in December 2014 based on the phase 3 CheckMate-037 study [48] . In this trial, 405 patients were assigned to either nivolumab or chemotherapy in a 2:1 ratio, [50] . Among these responders were three who had a complete response. An additional 14 (27%) patients had stable disease lasting more than 24 weeks. Common side effects included infusion-related reactions (10%), diarrhea (9%), and rash (7%). Grade 3 or higher adverse events were uncommon (9%). Another anti-PD-L1 antibody (MPDL3280A) is being explored in a phase 1 trial in patients with melanoma, renal cancer, non-small-cell lung cancer, and other tumor types [51] . Results from the melanoma cohort (n = 44) were reported, showing a 29% ORR in 38 evaluable patients.
The responses were durable with 10 of 11 patients continuing with therapy at the time of study report. In this group of patients, no dose-limiting adverse events were noted with common adverse events including fatigue, headache, diarrhea, and pruritus. MPDL3280A is currently being combined with vemurafenib in a phase 1 trial for patients with BRAF V600 mutant melanoma.
ADJUVANT APPROACHES WITH IMMUNE CHECKPOINT INHIBITORS
In the adjuvant setting, the EORTC 18071 trial explored ipilimumab compared to placebo in 951 patients with stage III melanoma after wide local excision and lymph node resection [52] . 
COMBINATION IMMUNE CHECKPOINT INHIBITORS
Single-agent PD-1 inhibition with nivolumab and pembrolizumab has demonstrated higher rates of activity and tolerability compared to what has previously been seen with ipilimumab. However, the potential for the combination of a PD-1 inhibitor and ipilimumab has been highlighted in a series of phase 1, 2, and 3 trials [53] [54] [55] . In a striking phase 1 trial, the combination of ipilimumab and nivolumab in previously treated metastatic melanoma patients resulted in surprising response rates (range 21-53%) with both rapid and deep responses noted. An update on 1-and 2-year OS rates for this trial has been presented, and they are 82% and 75%, respectively, with a median OS of about 40 months [56] .
Additionally, of those patients obtaining a response, the bulk of these patients is seeing depths of tumor shrinkage of[80%, which is durable. Grade 3 or 4 adverse events were noted in 53% of patients, and the most common ones were elevated lipase and AST. A phase 2 trial confirmed the efficacy of the combination compared to ipilimumab and has now been published [54] . A three-arm placebo-controlled, Multiple preclinical studies and a few clinical studies showed a synergistic benefit of CTLA-4 blockade and GM-CSF-secreting tumor cell vaccines [57] [58] [59] . A phase 2 randomized trial enrolled 245 previously treated unresectable stage 3 or metastatic melanoma patients to ipilimumab plus sargramostim vs. ipilimumab alone [60] . At median follow-up duration of 13 months, there was no difference in PFS; however, the median OS significantly favored the sargramostim group at 17.5 versus 12.7 months. The 1-year OS rate for the combination was 68.9% compared to 52.9% for ipilimumab alone (HR 0.64, p = 0.01).
Interestingly, there was a reduction of toxicity in the combination group, particularly gastrointestinal and pulmonary adverse events.
The proposed mechanism for improved efficacy that resulted in increased OS is theorized to be an improved antigen presentation with GM-CSF via recruitment of dendritic cells and macrophages. However, it is also possible that the improved toxicity profile also may have impacted outcomes.
One unanswered question in the BRAF V600 mutated subset of melanoma patients is whether to use initial therapy focused on the BRAF pathway, target immune checkpoints or utilize a combination of these approaches.
There are a variety of trials seeking to answer these questions, including trials comparing upfront ipilimumab and nivolumab versus dabrafenib and trametinib followed by cross-over on progression (NCT02224781), combining nivolumab with dabrafenib and/or trametinib (NCT02357732), and combining pembrolizumab with dabrafenib and trametinib (NCT02130466).
OTHER AGENTS IN DEVELOPMENT
A variety of other approaches are being pursued for melanoma therapy that can activate the immune system in other ways. One agent that has been tested in a phase 3 trial is talimogene laherparepvec, also known as TVEC. This agent is a modified herpes simplex virus that has been designed to replicate in tumor cells and transcribe granulocyte macrophage colony-stimulating factor (GM-CSF) [61] . The virus must be directly injected into tumors where it can multiply and cause cell lysis and release of GM-CSF into the tumor microenvironment. The GM-CSF can then attract immune cells such as dendritic cells that can stimulate an anticancer immune response. TVEC has been studied in a phase 3 trial of 436 metastatic or unresectable melanoma patients who were randomized to receive either T-VEC intratumoral injections or subcutaneous GM-CSF [62] . The primary endpoint was a durable response rate with secondary endpoints of the overall response rate and overall survival. The durable response rate for TVEC was noted to be 16.3% compared to 2.1% for GM-CSF (p\0.01). The response rate was also higher at 26.4% compared to 5.7%.
A trend toward improved overall survival was noted but not statistically significant (p = 0.051). Common side effects with T-VEC included fatigue, chills, and pyrexia. TVEC has been submitted to the FDA for approval;
however, final FDA approval is pending.
Criticisms of the study include the GM-CSF control arm, which was given the treatment subcutaneously rather than intra-tumorally. Additionally, GM-CSF is known to have no Finally, adoptive T-cell therapy is an investigational approach to immunotherapy, which has been under study for over several decades [64] . Targeted approaches for non-BRAF mutant However, combinational approaches such as combining immune checkpoint inhibitors with each other, with other immunotherapies, and with molecularly targeted drugs may expand on these outcomes. Based on recent positive clinical studies, it is anticipated that nivolumab and pembrolizumab will become FDA approved in the front-line setting, and potentially the nivolumab and ipilimumab combination will also become approved. The optimal sequence and combination of targeted drugs and immunotherapies are still unknown and remain an active area of clinical research. One area of concern is the potential cost burden that these new agents may introduce for patients and society. For example, a course of ipilimumab has the potential to cost over $100,000. The other immune checkpoint inhibitors and oral targeted agents also have a similar degree of cost, particularly if patients remain on them for many months. For patients receiving no benefit high costs add an extra burden; however, for patients that achieve long-term survival these costs may be viewed through a different lens, and a positive return for the high cost is more tangible. Although many factors go into the cost of drugs, including the price of development of new agents, this issue drives the need for improved biomarkers to help select patients who would benefit from a particular agent so that patients who will not benefit can avoid both the toxicity of the drug as well as the cost.
With that said, it is difficult to deny that the advances that have been made in therapeutic development for metastatic melanoma over the last few years are quite astonishing. The sharp rise in response rates from 10% with the older drugs to[50% with newer agents has given the treating physician agents which are much more likely to palliate cancer-related symptoms and thus improve quality of life. Additionally, these new drugs have extended survival of the average patient, which over the last several decades has never been done before. Not only is the average survival of the metastatic melanoma patient improving for the first time in history, but there is a large, currently undefined subset of patients who have the potential to experience a long term survival advantage measured in years, not months. Of all things, this gives us hope, that as we progress towards an improved understanding of how to use these currently approved and upcoming drugs, we will see the elimination of this once dismal disease in our lifetime.
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